First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Epigral: the story is balanced — New customer contract wins and capacity expansion announcements, particularly with multinational agrochemical/pharma…
★ Analysts see FY2027 revenue reaching $30.1B — +20.4% growth in a single year.
What Moves the Stock
1New customer contract wins and capacity expansion announcements, particularly with multinational agrochemical/pharma companies seeking supply chain diversification from China
2Raw material cost inflation (crude oil derivatives, natural gas, specialty feedstocks) and ability to pass through costs via contractual mechanisms
3Capacity utilization rates across manufacturing facilities - specialty chemical plants typically need 70-80% utilization for profitability
4Regulatory developments affecting agrochemical approvals or pharmaceutical API sourcing requirements in key export markets (US, EU)
5Chinese specialty chemical supply dynamics and competitive pricing pressure from state-subsidized producers
6Agrochemical intermediates and active ingredients (estimated 40-50% of revenue based on Indian specialty chemical sector composition)
7Pharmaceutical intermediates and APIs for generic drug manufacturers (estimated 25-35%)
8Industrial chemicals and performance materials for manufacturing applications (estimated 15-25%)
growth - The 34.7% revenue growth, 82.6% net income growth, and 79.6% EPS growth attract growth investors seeking exposure to India's…
Rising interest rates create moderate headwinds through higher working capital financing costs (specialty chemicals require significant…
Watch on earnings: Brent crude oil price (BZUSD) - primary feedstock cost driver for petrochemical-derived specialty chemical inputs, Natural gas prices (NGUSD) - critical energy input for chemical synthesis and utilities in manufacturing operations, Indian rupee vs USD exchange rate (inverse of DEXCHUS) - affects export competitiveness and revenue translation.
One Sentence Summary:
Epigral: the story is balanced — new customer contract wins and capacity expansion announcements, particularly with multinational agrochemical/pharma companies seeking.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.